Literature DB >> 9591638

DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma.

A M Björkqvist1, K Husgafvel-Pursiainen, S Anttila, A Karjalainen, L Tammilehto, K Mattson, H Vainio, S Knuutila.   

Abstract

We performed a comparative genomic hybridization study on 25 samples of adenocarcinoma and 19 samples of squamous cell carcinoma of the lung to detect recurrent changes in the genetic material. DNA copy number changes were found in 16 squamous cell carcinoma samples and 17 adenocarcinoma samples. The most common changes were gains of DNA sequences in 3q (43%), 1q (34%), 8q (32%), 5p, (30%), 7p (25%), and 12p (25%). Of the squamous cell carcinoma samples with DNA copy number changes, 94% (15/16) had a gain in 3q (minimal common region of overlap q24-qter), whereas only 24% (4/17) of the adenocarcinoma samples with DNA copy number changes showed a gain in 3q (q22-qter) (P < 0.001). Six high-level amplifications in 3q (q26.2-q26.3) were detected in the squamous cell carcinoma samples but none were observed in the adenocarcinoma samples. Our results suggest that amplification of genes in 3q may be important in the tumorigenesis of squamous cell carcinoma but not necessarily of adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591638

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  36 in total

1.  Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization.

Authors:  L A Bryce; N Morrison; S F Hoare; S Muir; W N Keith
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Mutation and expression of the p51 gene in human lung cancer.

Authors:  M Tani; K Shimizu; C Kawahara; T Kohno; O Ishimoto; S Ikawa; J Yokota
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

Review 3.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

Review 4.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

5.  The chromosome 3q26 OncCassette: A multigenic driver of human cancer.

Authors:  Alan P Fields; Verline Justilien; Nicole R Murray
Journal:  Adv Biol Regul       Date:  2015-12-23

Review 6.  Pulmonary adenocarcinoma: a renewed entity in 2011.

Authors:  Humam Kadara; Mohamed Kabbout; Ignacio I Wistuba
Journal:  Respirology       Date:  2012-01       Impact factor: 6.424

7.  Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas.

Authors:  Bhuvanesh Singh; Archontoula Stoffel; Swarna Gogineni; Ashok Poluri; David G Pfister; Ashok R Shaha; Alok Pathak; George Bosl; Carlos Cordon-Cardo; Jatin P Shah; Pulivarthi H Rao
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Role of p63 in Development, Tumorigenesis and Cancer Progression.

Authors:  Johann Bergholz; Zhi-Xiong Xiao
Journal:  Cancer Microenviron       Date:  2012-07-31

9.  Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens.

Authors:  Henry M Wood; Ornella Belvedere; Caroline Conway; Catherine Daly; Rebecca Chalkley; Melissa Bickerdike; Claire McKinley; Phil Egan; Lisa Ross; Bruce Hayward; Joanne Morgan; Leslie Davidson; Ken MacLennan; Thian K Ong; Kostas Papagiannopoulos; Ian Cook; David J Adams; Graham R Taylor; Pamela Rabbitts
Journal:  Nucleic Acids Res       Date:  2010-06-04       Impact factor: 16.971

Review 10.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.